Logo

Cepheid

Updated Cepheid SARS-CoV-2, Flu, RSV Test Nabs FDA EUA

The new version of the multiplex test adds a third gene target for SARS-CoV-2 to detect future viral mutations.

Cepheid Gets $28M From BARDA for SARS-CoV-2 Tests

The funding is for the firm's SARS-CoV-2, pan-coronavirus, and multiplex SARS-CoV-2, influenza, and respiratory syncytial virus tests, according to BARDA.

Cepheid Nabs CE Mark for PCR-Based HIV-1 Tests

Both tests run on any of the firm's GeneXpert systems and add second targets for HIV detection and early identification.

Pandemic Pushes Handheld qPCR Devices Closer to Commercialization
Premium

Miniaturized sample-to-answer devices in development hint at an evolving molecular diagnostics landscape but launch timelines for these platforms remain unclear.

Demand for Cepheid SARS-CoV-2 Point-of-Care Tests Expected to Continue Through 2022
Premium

The Danaher subsidiary's core revenues grew more than 90 percent in the first quarter of 2021 and it expects to ship 45 million SARS-CoV-2 tests for the year.

Apr 22, 2021

Danaher Q1 Revenues Up 58 Percent

Apr 13, 2021

Danaher Expects Q1 2021 Revenue Growth Above Previous Guidance

Mar 31, 2021

FDA Posts Info on Impact of SARS-CoV-2 Mutations on Test Effectiveness

Feb 18, 2021

WHO Finds High Diagnostic Accuracy in Three Classes of MDx Technologies for TB Testing, Resistance

Jan 28, 2021

Danaher Q4 Revenues up 39 Percent

Dec 29, 2020

Cepheid Gets FDA Emergency Use Authorization for US Department of Defense Coronavirus Test

Dec 1, 2020

Cepheid, Roche Coronavirus Tests Get FDA Emergency Use Authorization

Nov 24, 2020

Cepheid Receives CE Mark for SARS-CoV-2, Flu A/B, RSV Combination Test

Nov 17, 2020

Cepheid Developing New Target for BCR-ABL Test for Leukemia Patients
Premium

Oct 22, 2020

Danaher Q3 Revenues Up 35 Percent

Oct 9, 2020

India Banks on Decentralized Molecular COVID-19 Testing
Premium

Sep 25, 2020

Cepheid Multiplex SARS-CoV-2, Flu, RSV Test Nabs FDA Emergency Use Authorization

Sep 8, 2020

As Flu Season Nears, Dx Companies Shift Attention to Multiplex Tests for SARS-CoV-2, Influenza
Premium

Jul 31, 2020

SARS-CoV-2 E Gene SNP Raises Concerns About Test Accuracy, Transparency
Premium

Jul 23, 2020

Danaher Q2 Revenues Spike 19 Percent

Jul 21, 2020

AdvaMed Partners With Dx Companies to Create National COVID-19 Supply Registry

Jul 17, 2020

Cepheid Debuts 10-Color Molecular Detection Technology With New Tuberculosis Test
Premium

May 14, 2020

New Study Finds Abbott's ID Now SARS-CoV-2 Test Misses Sensitivity Mark

May 7, 2020

Danaher Q1 Revenues Up 3 Percent; Joyce Retiring as CEO

Apr 15, 2020

CMS Increases Payment Rates for High-Throughput SARS-CoV-2 Tests

Breaking News
The Scan

US Booster Eligibility Decision

The US CDC director recommends that people at high risk of developing COVID-19 due to their jobs also be eligible for COVID-19 boosters, in addition to those 65 years old and older or with underlying medical conditions.

Arizona Bill Before Judge

The Arizona Daily Star reports that a judge is weighing whether a new Arizona law restricting abortion due to genetic conditions is a ban or a restriction.

Additional Genes

Wales is rolling out new genetic testing service for cancer patients, according to BBC News.

Science Papers Examine State of Human Genomic Research, Single-Cell Protein Quantification

In Science this week: a number of editorials and policy reports discuss advances in human genomic research, and more.